Elicio Therapeutics Target of Unusually Large Options Trading (NASDAQ:ELTX)

Elicio Therapeutics, Inc. (NASDAQ:ELTX) was the recipient of unusually large options trading on Monday. Stock investors purchased 8,943 call options on the company. This is an increase of 1,664% compared to the average volume of 507 call options.

Wall Street Analyst Weigh In

ELTX has been the topic of a number of research analyst reports. LADENBURG THALM/SH SH initiated coverage on Elicio Therapeutics in a research note on Wednesday, April 15th. They issued a “buy” rating and a $20.00 price target on the stock. HC Wainwright lifted their price target on Elicio Therapeutics from $17.00 to $23.00 and gave the stock a “buy” rating in a research note on Monday. Wall Street Zen downgraded Elicio Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Elicio Therapeutics in a research report on Friday, April 24th. Finally, B. Riley Financial assumed coverage on Elicio Therapeutics in a research report on Wednesday, June 10th. They set a “buy” rating and a $27.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.75.

Elicio Therapeutics Trading Down 72.6%

Shares of Elicio Therapeutics stock traded down $10.79 during mid-day trading on Monday, hitting $4.07. The stock had a trading volume of 8,014,811 shares, compared to its average volume of 202,040. Elicio Therapeutics has a 12-month low of $3.62 and a 12-month high of $16.00. The company has a quick ratio of 2.24, a current ratio of 2.24 and a debt-to-equity ratio of 5.75. The firm has a market cap of $77.58 million, a P/E ratio of -1.69 and a beta of 1.13. The firm has a 50-day moving average of $11.36 and a two-hundred day moving average of $9.96.

Elicio Therapeutics (NASDAQ:ELTX) last posted its earnings results on Monday, May 11th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.16). Sell-side analysts forecast that Elicio Therapeutics will post -2.09 earnings per share for the current year.

Institutional Investors Weigh In On Elicio Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Elicio Therapeutics by 4.2% in the third quarter. Vanguard Group Inc. now owns 473,859 shares of the company’s stock valued at $5,184,000 after purchasing an additional 19,240 shares during the period. Geode Capital Management LLC raised its position in Elicio Therapeutics by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 132,518 shares of the company’s stock valued at $1,055,000 after purchasing an additional 2,832 shares during the period. Renaissance Technologies LLC raised its position in Elicio Therapeutics by 332.7% in the first quarter. Renaissance Technologies LLC now owns 121,631 shares of the company’s stock valued at $1,300,000 after purchasing an additional 93,520 shares during the period. Susquehanna International Group LLP raised its position in Elicio Therapeutics by 606.1% in the third quarter. Susquehanna International Group LLP now owns 120,207 shares of the company’s stock valued at $1,315,000 after purchasing an additional 103,184 shares during the period. Finally, Marshall Wace LLP raised its position in Elicio Therapeutics by 35.4% in the fourth quarter. Marshall Wace LLP now owns 117,200 shares of the company’s stock valued at $933,000 after purchasing an additional 30,667 shares during the period. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.